drugset / Trial / NCT03081832

Follow-up of Prader Willi Syndrome Infants Treated by Oxytocin and Comparison With Not-treated Infants.

NCT03081832 ↗

Completed 34 enrolled University Hospital, Toulouse
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The objective of this study is to collect data on tolerance and effects of early treatment with oxytocin in children with Prader Willi Syndrome aged from 3 to 4 years and to compare these infants with not treated age-matched infants with Prader Willi Syndrome.

Timeline

Start
2017-01
Primary completion
2018-05
Completion
2018-12

Outcome

Missed primary endpoint

paper The VABS-II communication score was not different between the two groups, defined as OT-exposed and non-exposed PMID 40025514 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxytocin Peptide — Intranasal

Indications